Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Innate Pharma S.A. IPH.PA
$2.71
-$0.1 (-3.57%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
224970537.00000000
-
week52high
3.80
-
week52low
1.99
-
Revenue
49639000
-
P/E TTM
-2
-
Beta
0.32213700
-
EPS
-0.69000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 05:00
Описание компании
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
SVB Leerink | Market Perform | Market Perform | 19 мар 2021 г. |
SVB Leerink | Market Perform | Outperform | 15 дек 2020 г. |
HC Wainwright & Co. | Buy | Buy | 14 дек 2020 г. |
Goldman Sachs | Neutral | 24 ноя 2020 г. | |
SVB Leerink | Outperform | Outperform | 09 сент 2020 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии